Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.59 |
| ▸ | USP2 | O75604 | 7/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.46 |
| ▸ | TSHR | P16473 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.42 |
| ▸ | TP53 | P04637 | 5/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.42 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.42 |
| ▸ | HTR3B | O95264 | 1/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.42 |
| ▸ | HTR3A | P46098 | 1/20 | 0.42 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.42 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8093116 | 0.82 | OPRM1 (0.47) | HSD17B10SIGMAR1DDB1CRBNOPRM1 | |
| SCHEMBL15446972 | 0.81 | BDKRB2 (0.51) | TSHRSIGMAR1OPRM1OPRD1OPRK1 | |
| SCHEMBL219618 | 0.74 | HSD17B10 (1.00) | HSD17B10OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL7587764 | 0.74 | HSD17B10 (1.00) | HSD17B10OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL4355371 | 0.73 | HSD17B10 (0.57) | HSD17B10USP2CYP2D6TSHRALDH1A1 | |
| Hydrochloric Acid SCHEMBL6160546 | 0.73 | HSD17B10 (0.97) | HSD17B10OPRM1OPRD1OPRK1OPRL1 | |
| Ammonia Solution, Strong SCHEMBL1764035 | 0.73 | HSD17B10 (0.97) | HSD17B10OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL20187016 | 0.73 | HSD17B10 (0.57) | HSD17B10USP2CYP2D6TSHRDDB1 | |
| Hydrochloric Acid SCHEMBL7013712 | 0.73 | OPRM1 (0.64) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL3067132 | 0.72 | OPRL1 (0.61) | HSD17B10USP2CYP2D6TSHROPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | ASTRAZENECA AB (SE) | 2009-03-12 | — | — | US | disclosed |
| EP-1833800-A1 | PYRAZOLONE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR AGONISTS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | AstraZeneca AB (SE) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006071730-A1 | PYRAZOLONE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR AGONISTS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | ASTRAZENECA AB (SE) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | GRIN1, GRM1, GRIN3A | HSD17B10 2056/4885USP2 3668/4885CYP2D6 2016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.